Free Trial
NASDAQ:AADI

Aadi Bioscience (AADI) Stock Price, News & Analysis

$1.84
+0.02 (+1.10%)
(As of 05/24/2024 04:00 PM ET)
Today's Range
$1.80
$1.88
50-Day Range
$1.68
$2.37
52-Week Range
$1.55
$8.49
Volume
265,500 shs
Average Volume
321,776 shs
Market Capitalization
$45.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.50

Aadi Bioscience MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,014.1% Upside
$20.50 Price Target
Short Interest
Bearish
6.50% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.25mentions of Aadi Bioscience in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$202,939 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.54) to ($2.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.56 out of 5 stars

Medical Sector

511th out of 922 stocks

Pharmaceutical Preparations Industry

227th out of 426 stocks

AADI stock logo

About Aadi Bioscience Stock (NASDAQ:AADI)

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

AADI Stock Price History

AADI Stock News Headlines

Arlo Technologies: Q1 Earnings Snapshot
AADI Apr 2024 10.000 call
AADI Oct 2024 2.500 put
AADI Jul 2024 2.500 put
Aadi Bioscience Earnings Preview
See More Headlines
Receive AADI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
5/27/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AADI
Fax
N/A
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.50
High Stock Price Target
$36.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,014.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-65,760,000.00
Net Margins
-288.72%
Pretax Margin
-288.72%

Debt

Sales & Book Value

Annual Sales
$24.35 million
Book Value
$4.29 per share

Miscellaneous

Free Float
15,395,000
Market Cap
$45.17 million
Optionable
Optionable
Beta
0.64
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Neil P. Desai Ph.D. (Age 59)
    Founder & Executive Chairman
    Comp: $710.35k
  • Mr. David J. Lennon Ph.D. (Age 53)
    President, CEO & Director
    Comp: $277.75k
  • Mr. Scott M. Giacobello CPA (Age 54)
    CFO, Treasurer, Investor Relations & Corporate Communications
    Comp: $643.23k
  • Dr. Loretta M. Itri F.A.C.P. (Age 74)
    M.D., Chief Medical Officer
    Comp: $617.45k
  • Mr. Stephen M. Rodin J.D. (Age 48)
    Senior VP of Legal & General Counsel
  • Mr. Raymond G. Steitz (Age 65)
    Senior VP of Human Resources & Chief Human Resources Officer
  • Mr. Bryan Ball (Age 54)
    Chief Quality Officer & Senior VP of Manufacturing Operations

AADI Stock Analysis - Frequently Asked Questions

Should I buy or sell Aadi Bioscience stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aadi Bioscience in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AADI shares.
View AADI analyst ratings
or view top-rated stocks.

What is Aadi Bioscience's stock price target for 2024?

2 equities research analysts have issued 1-year price targets for Aadi Bioscience's stock. Their AADI share price targets range from $5.00 to $36.00. On average, they expect the company's share price to reach $20.50 in the next year. This suggests a possible upside of 1,014.1% from the stock's current price.
View analysts price targets for AADI
or view top-rated stocks among Wall Street analysts.

How have AADI shares performed in 2024?

Aadi Bioscience's stock was trading at $2.02 at the beginning of 2024. Since then, AADI shares have decreased by 8.9% and is now trading at $1.84.
View the best growth stocks for 2024 here
.

When is Aadi Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our AADI earnings forecast
.

How were Aadi Bioscience's earnings last quarter?

Aadi Bioscience, Inc. (NASDAQ:AADI) posted its earnings results on Wednesday, March, 13th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.07. The company had revenue of $6.33 million for the quarter, compared to the consensus estimate of $6.46 million. Aadi Bioscience had a negative trailing twelve-month return on equity of 61.83% and a negative net margin of 288.72%.

When did Aadi Bioscience's stock split?

Aadi Bioscience's stock reverse split on Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Aadi Bioscience's major shareholders?

Aadi Bioscience's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Marquette Asset Management LLC (0.24%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Caley Castelein and Neil Desai.
View institutional ownership trends
.

How do I buy shares of Aadi Bioscience?

Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AADI) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners